Projects co-funded by the European Union

PHOTOVOLTAIC POWER PLANT

Project No.: CZ.31.3.0/0.0/0.0/22_001/0001545

is co-financed by the European Union.

The project aims to install a photovoltaic power plant for the applicant’s own consumption. The use of renewable energy sources will optimise the electricity supply for business operations.

EXPANSION OF THE R&D FACILITY FOR ACTIVE PHARMACEUTICAL INGREDIENTS

Project No.: CZ.01.01.01/03/23_024/0002664

Operational Programme: Technologies and Applications for Competitiveness
Call number and title: 01_23_024_Potential – Call I
Project title: FARMAK – Expansion of the R&D Facility for Active Pharmaceutical Ingredients
Beneficiary: FARMAK, a.s.

‍

The project “FARMAK – Expansion of the R&D Facility for Active Pharmaceutical Ingredients” involves the acquisition of analytical instruments. Its objective is to improve instrumentation for research and development of new generic active pharmaceutical ingredients. Emphasis is placed on understanding causal factors in manufacturing, reducing the risk of contamination, and meeting the requirements of a science-based approach to manufacturing and products.

‍THIS PROJECT IS CO-FINANCED BY THE EUROPEAN UNION FROM THE EUROPEAN REGIONAL DEVELOPMENT FUND UNDER THE TECHNOLOGIES AND APPLICATIONS FOR COMPETITIVENESS OPERATIONAL PROGRAMME, UNDER THE AUSPICES OF THE MINISTRY OF INDUSTRY AND TRADE.

QUALITY ASSURANCE FOR NEWLY DEVELOPED PRODUCTS

Project No.: CZ.01.01.01/03/23_024/0002664

Expansion of the existing research and innovation capacity to increase the competitiveness of FARMAK, a.s.

The research infrastructure is available to other users as a commercial service.

Available technologies for R&D:

• Jacketed glass laboratory reactors with accessories
• Instrument for particle-size measurement and determination of particle-size distribution
• Climate chambers for simulating storage and ageing conditions

VACUUM DRYING AND HOMOGENISATION TECHNOLOGY IN THE MANUFACTURE OF ACTIVE PHARMACEUTICAL INGREDIENTS

is co-financed by the European Union.

The project aims to modernise and expand active pharmaceutical ingredient manufacturing capacity, providing a higher level of protection for products, operators and the environment by upgrading final-product processing operations.

EXPANSION OF THE COMPANY’S DEVELOPMENT CAPACITY

is co-financed by the European Union.

The main objective of the project is to establish and develop the development centre’s capacity in research and development of innovative products, validated processes and technologies. The purpose of the project was to expand research and development infrastructure. The research infrastructure is available to other users as a commercial service.

Available technologies for R&D:

• Hydrogenation unit with a 50-litre high-pressure autoclave
• Differential scanning calorimeter

OPTIMISATION OF THE WASTE-GAS TREATMENT SYSTEM AT THE COMPANY

is co-funded by the European Union.

The main objective of the project is to establish and develop the capacity of the development centre for the research and development of innovative products and validated processes and technologies. The purpose of the project was to expand the research and development infrastructure. Other users may access the research infrastructure as a commercial service.

Available technologies for R&D:

• Hydrogenation unit with a 50-litre high-pressure autoclave
• Differential scanning calorimeter

SUPPORT FOR THE COMPANY’S PARTICIPATION IN INTERNATIONAL TRADE FAIRS

is co-funded by the European Union.

The aim of the project is to support FARMAK, a.s. in participating in international exhibitions and trade fairs in Europe and worldwide, in line with the applicant’s export strategy for 2017–2019.

SUPPORT FOR THE COMPANY’S PARTICIPATION IN INTERNATIONAL TRADE FAIRS

is co-funded by the European Union.

The aim of the project is to support FARMAK, a.s. in participating in international exhibitions and trade fairs in Europe and worldwide, in line with the applicant’s export strategy for 2017–2019.

IMPROVING THE QUALITY AND SAFETY OF ACTIVE PHARMACEUTICAL INGREDIENTS UNDER DEVELOPMENT AT THE COMPANY

is co-funded by the European Union.

The main objective of the project is to expand R&D capacity by acquiring an X-ray powder diffractometer, thereby increasing R&D efficiency and competitiveness, as well as the quality and consequently the safety of active pharmaceutical ingredients under development and subsequently manufactured.

INNOVATION OF MANUFACTURING PROCESSES AT THE COMPANY

is co-funded by the European Union.

The aim of the project is to introduce a patent-non-infringing and economical method for manufacturing new products. A further objective is to implement an innovative manufacturing process in a newly built, stand-alone production unit featuring a new approach to product and intermediate isolation.